A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 9710041.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We studied the effect of i.v. administration of a dehydroepiandrosterone sulfate (DHEAS) preparation (200 mg/day for 8 weeks) in 11 patients with myotonic dystrophy (MyD). After DHEAS, activities of daily living improved, muscle strength increased, and myotonia decreased. Conduction block and premature beats also improved in the four patients with cardiac involvement. This pilot study may provide a rationale for a controlled study of DHEAS in MyD.
Medical subject headings
- Dehydroepiandrosterone Sulfate
- Myotonic Dystrophy